3 completed. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow ChimeriVax: new trials by email Literature Review of ChimeriVax trials Research Report on ChimeriVax
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects CYD dengue vaccine serotypes (1, 2, 3, 4)., Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide - Dengue Virus, Dengue Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 180 | 2009-03-01 | 2022-04-05 |
| Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years CYD Dengue Vaccine Serotypes 1, 2, 3, and 4, Pneumococcal polysaccharide vaccine - Dengue Virus, Dengue Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 300 | 2008-09-26 | 2022-04-05 |
| Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis. ChimeriVax-JE, Japanese Encephalitis vaccine, 0.9% Saline - Encephalitis, Japanese Encephalitis | Phase 3 | Completed | Sanofi | 2004 | 2005-10-01 | 2012-12-06 |
Dengue (2) · Severe Dengue (2) · Encephalitis (1) · Encephalitis, Japanese (1)
Sanofi Pasteur, a Sanofi Company (2) · Sanofi (1)
Australia (1) · Peru (1) · United States (1) · Vietnam (1)
2014 (2)